The Procaps Group announces the appointment of Melissa Angelini as Director of Investor Relations

Pharmaceutical industry and investor relations veteran to lead capital markets communications strategy

BARRANQUILLA, Colombia, January 28, 2022–(BUSINESS WIRE)–Procaps Group (NASDAQ: PROC), a leading integrated international pharmaceutical and healthcare company, today announced the appointment of Melissa Angelini as Director of Investor Relations, effective February 1 2022.

This press release is multimedia. See the full version here:

Melissa Angelini, Director of Investor Relations at Procaps Group (Photo: Business Wire)

Melissa Angelini is a seasoned executive with over 15 years of experience in capital markets and investor relations with pharmaceutical and healthcare companies. She has extensive experience with clients in Latin American countries including Brazil, Mexico, Argentina, Chile, Colombia and Peru. Previously, she was Head of Innovation and Investor Relations at Blau Farmacêutica, a Brazilian multinational pharmaceutical company with a market capitalization of $1 billion. Angelini also served as LATAM Head of Alliance Management and Investor Relations at GBT Grupo Biotoscana, a Latin American healthcare company. There she co-led Grupo Biotoscana’s IPO in 2017 through a deal that was oversubscribed about 5 times and raised BRL 1.342 billion (US$429 million). It was the largest health care IPO in Latin America since 2011 and the largest health care IPO in the Americas in 2017. She was also executive director of relationships with investors at MZ Group, the world’s largest independent investor relations firm, where she was Head of Investor Relations. and the Strategic Partnerships department and managed some of the largest accounts in Latin America. Melissa holds an MBA in Finance from Insper Instituto de Ensino e Pesquisa, Brazil, and is fluent in English, Spanish and Portuguese.

“Melissa brings a wide range of investor relations and capital markets experience in pharmaceutical companies that will benefit Procaps as we accelerate the delivery of our innovative pharmaceutical solutions and drive new expansion initiatives. He is important to note that this new position will ultimately be based out of our Aventura, FL as we expand our footprint in the United States,” said Patricio Vargas, Procaps Group CFO. “Melissa is a deeply experienced investor relations professional. and respected, and his expertise in communicating our strategy and growth opportunities externally will be instrumental as we continue to strengthen our investor and industry relationships with key stakeholders.”

Angelini added: “I am honored to join Procaps at such an exciting inflection point for the business. With their recent US listing on the Nasdaq and the announcement of increased production capacity in the US, I will be very focused on communicating Procaps. story to a growing group of investors and shareholders around the world.”

About the Procaps Group

Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies that reach more than 50 countries on five continents. Procaps has a direct presence in 13 Latin American countries and more than 4,500 employees working according to a sustainable model. Procaps develops, manufactures and markets over-the-counter (“OTC”) and prescription (“Rx”) pharmaceutical drugs, nutritional supplements and high potency clinical solutions. For more information, visit or the Procaps Group investor relations site

Forward-looking statements

This press release contains “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “anticipate”, “intend”, “seek”, “target”, “anticipate”, “believe”, “expect”, ” estimate”, “plan”, “outlook” and “project” and other similar expressions which predict or indicate future events or trends or which are not statements of historical matters. These forward-looking statements regarding the performance, strategies, synergies, prospects and other aspects of the business of Procaps Group SA (“Procaps Group”) are based on current expectations which are subject to risks and uncertainties. A number of factors could cause actual results or results to differ materially from those indicated by these forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from the information expressed or implied by these forward-looking statements. Although we believe we have a reasonable basis for each forward-looking statement contained in this press release, we caution that such statements are based on a combination of facts and factors currently known to us and our projections for the future, about of which we cannot be certain. We cannot assure you that the forward-looking statements contained in this press release will prove to be accurate. These forward-looking statements are subject to a number of important risks and uncertainties that could cause actual results to differ materially from expected results, including, among other things, the impact of COVID-19 on the Procaps Group’s business. , changes in applicable laws or regulations, the possibility that Procaps Group may be adversely affected by other economic, business and/or competitive factors, and other risks and uncertainties, including those included under the heading “ Risk Factors” in the Form F-1 registration statement filed with the US Securities and Exchange Commission (“SEC”), as well as Procaps Group’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should one of our assumptions prove incorrect, actual results may differ materially from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not place undue reliance on such statements.

See the source version on


Investor contacts:
chris tyson
Executive Vice President
MZ North America
Direct: 949-491-8235

Comments are closed.